Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PD-1/L1
Biotech
Are Lilly, Novartis eyeing the PD-1xVEGF field? Execs weigh in
Both Eli Lilly and Novartis once had their PD-1 inhibitor dreams shattered, and both know the VEGF realm.
Angus Liu
Jun 4, 2025 1:00pm
BMS inks $11B biobucks BioNTech deal to join bispecific rush
Jun 2, 2025 8:59am
Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific
May 20, 2025 4:47am
Will Novartis catch the PD-1 bispecific wave? CEO weighs in
Jan 31, 2025 3:30am
BioNTech posts overall survival data on would-be Keytruda killer
Dec 10, 2024 9:00am
Gilead and Arcus' TIGIT combo continues to show signs of life
Jun 3, 2023 1:30pm
